Quadrant Capital Group
TRDA icon

Quadrant Capital Group’s Entrada Therapeutics TRDA Stock Holding History

Quadrant Capital Group’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18
Closed -$228 – 2475
2026
Q1 		$228 Buy
+18
New +$206 ﹤0.01% 2660

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5AM Venture Management
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Merck & Co
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MPM BioImpact
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
StepStone Group
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Quadrant Capital Group's TRDA Position: Q2 2026 in Review

Quadrant Capital Group sold out of Entrada Therapeutics (TRDA) in Q2 2026, closing a stake of 18 shares — an estimated $228 sold.

Quadrant Capital Group first reported a position in TRDA in Q1 2026 and held it in 1 quarter. The position peaked at $228 in Q1 2026. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Quadrant Capital Group reported no remaining Entrada Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 18 Entrada Therapeutics shares in Q2 2026, an estimated $228.
  • Quadrant Capital Group first reported a position in Entrada Therapeutics in Q1 2026 and held it in 1 quarter.
  • Quadrant Capital Group's Entrada Therapeutics position peaked at $228 in Q1 2026.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.